Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.
about
Epigenetic polypharmacology: from combination therapy to multitargeted drugsFas Versatile Signaling and Beyond: Pivotal Role of Tyrosine Phosphorylation in Context-Dependent Signaling and DiseasesDecitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivoCeramide mediates FasL-induced caspase 8 activation in colon carcinoma cells to enhance FasL-induced cytotoxicity by tumor-specific cytotoxic T lymphocytesSorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs.Interdiction of sphingolipid metabolism to improve standard cancer therapies.A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels.Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response.PDE5 inhibitors enhance celecoxib killing in multiple tumor types.Alteration of ceramide synthase 6/C16-ceramide induces activating transcription factor 6-mediated endoplasmic reticulum (ER) stress and apoptosis via perturbation of cellular Ca2+ and ER/Golgi membrane network.Expression of Ceramide Synthase 6 Transcriptionally Activates Acid Ceramidase in a c-Jun N-terminal Kinase (JNK)-dependent MannerCombination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.Identification of initial leads directed at the calmodulin-binding region on the Src-SH2 domain that exhibit anti-proliferation activity against pancreatic cancerEndogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.Concerted functions of HDAC1 and microRNA-574-5p repress alternatively spliced ceramide synthase 1 expression in human cancer cells.Differential regulation of autophagy and cell viability by ceramide species.Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress.Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95Nexavar/Stivarga and viagra interact to kill tumor cells.GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient.Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor TherapeuticCeramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progressionPhase I study of pemetrexed with sorafenib in advanced solid tumors.Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.Ceramide activates lysosomal cathepsin B and cathepsin D to attenuate autophagy and induces ER stress to suppress myeloid-derived suppressor cells.Novel chemotherapeutic drugs in sphingolipid cancer research.The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance.Targeting the Fas/FasL signaling pathway in cancer therapy.Protein phosphatase 2A: a target for anticancer therapy.[pemetrexed + sildenafil], via autophagy-dependent HDAC down-regulation, enhances the immunotherapy response of NSCLC cells.Dual abrogation of MNK and mTOR: a novel therapeutic approach for the treatment of aggressive cancers.Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas.Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer.Preferential involvement of mitochondria in Toll-like receptor 3 agonist-induced neuroblastoma cell apoptosis, but not in inhibition of cell growth.Calmodulin mediates Fas-induced FADD-independent survival signaling in pancreatic cancer cells via activation of Src-extracellular signal-regulated kinase (ERK).[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.
P2860
Q28067666-3F72850A-9A1B-47A8-BB19-F9267A2D8A4EQ28073778-CB982E76-176A-4CD4-ADFD-222599314A9DQ28263221-ECCB98AF-410A-40A6-ADF0-A320A844A704Q30357159-B4798018-4DF8-4DC7-A2D3-523A60AD1B21Q33576187-03BD23B6-63B2-46DD-B11F-4E258B9C3AC4Q34289307-9B8C9632-3A63-4D2E-AA86-81D731529AE5Q34373466-AE1B96DF-0E2C-4C28-873B-40DA52B6A065Q34701049-E85B7A89-3DF1-4DC0-B4F3-A0BADB71280BQ35223807-A62AE254-2727-498B-8BCC-A97B560EB252Q35430943-331F6A47-4E32-4351-948F-DC29C0F082BCQ35605031-F74063AF-8DE8-4620-96C0-E149F17E1EA1Q35860939-B49BA566-72BA-4F1E-8573-05F52B42BEA6Q35895346-F7AA8686-9F36-43B6-8E97-D0DB464AEB68Q35902399-320FA4FA-5E90-4783-AF30-F31B214D3783Q35975127-1ECA5F88-4923-4248-896F-EB32BF0CC001Q36037926-2573A54A-18DB-48C2-A5FF-099F8E5F178CQ36214943-4374D103-131F-420E-8093-F8B76D6C7C3FQ36412836-E52E5428-2954-499C-B82B-9A30179AB864Q36782452-DD55E73B-82D3-4345-8AFA-39D418F9D243Q36808335-5E17EFA0-12A1-4513-91F5-8F62F5E4BFD3Q36830763-7EB25384-3DB6-4D12-A2F0-3D025773FD13Q36985683-48A8797A-E026-411B-A4D4-BCDEADE979D1Q36995729-257271E7-B900-4A8D-A934-8EAF91201D63Q37502782-979C3C01-AB87-4FB9-A216-D48D3D4C737CQ37520649-06ED8BF0-2FDE-4FE1-9E91-75D1ADFE7DFCQ37589245-E6DB18FA-FB7D-4D31-90FF-8485CE0EC1ADQ37708912-2F62F959-9A38-4942-B61F-4485F266EF6CQ37721276-2522992C-405F-4017-80FA-71907060717EQ37725434-FBF48B8F-CDDF-4FF3-96EA-AF9CC117A36DQ37808219-8EBDA9F0-DE8E-4011-A47A-ABA27930181BQ37975245-DB5215EF-4E40-4718-AD4E-BA8F51CA5AF8Q38103646-18E3CA20-7B09-428B-8915-34C6851D3AE6Q38622540-41D63E3E-8F8F-454B-8B0C-774EAEDDF4E6Q38637354-06B1A8AE-BC98-4BBA-AB7F-C2720D5CC622Q39040289-98BDC43A-E8B0-4F07-B627-DAEA404D9B33Q39381898-D355D4AF-E270-4666-B359-2C931D029B23Q39420607-0A7B5B87-13D9-44F9-9015-125BD5683729Q39424764-D68BC84A-34A9-4706-9FEA-A5F30A622EB3Q39536531-2270B5AB-1B1D-474C-87CB-DB993CDF8463Q39888747-7274F24C-A431-4458-81D2-7BEA6A4246E7
P2860
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Vorinostat and sorafenib incre ...... tinal tumor cells through a Ca
@nl
Vorinostat and sorafenib incre ...... s-dependent signaling pathway.
@en
type
label
Vorinostat and sorafenib incre ...... tinal tumor cells through a Ca
@nl
Vorinostat and sorafenib incre ...... s-dependent signaling pathway.
@en
prefLabel
Vorinostat and sorafenib incre ...... tinal tumor cells through a Ca
@nl
Vorinostat and sorafenib incre ...... s-dependent signaling pathway.
@en
P2093
P2860
P50
P1433
P1476
Vorinostat and sorafenib incre ...... s-dependent signaling pathway.
@en
P2093
Adly Yacoub
Andrew Larner
Besim Ogretmen
Christina Voelkel-Johnson
Clint Mitchell
Jeremy Allegood
Margaret A Park
Paul B Fisher
Roland Reinehr
P2860
P304
P356
10.1158/0008-5472.CAN-10-0999
P407
P577
2010-07-14T00:00:00Z